MX2023013017A - Anticuerpos anti citolítico natural grupo 2, miembro d (nkg2d) y usos de estos. - Google Patents

Anticuerpos anti citolítico natural grupo 2, miembro d (nkg2d) y usos de estos.

Info

Publication number
MX2023013017A
MX2023013017A MX2023013017A MX2023013017A MX2023013017A MX 2023013017 A MX2023013017 A MX 2023013017A MX 2023013017 A MX2023013017 A MX 2023013017A MX 2023013017 A MX2023013017 A MX 2023013017A MX 2023013017 A MX2023013017 A MX 2023013017A
Authority
MX
Mexico
Prior art keywords
nkg2d
antibodies
nkg2d antibodies
disclosed
cdrs
Prior art date
Application number
MX2023013017A
Other languages
English (en)
Spanish (es)
Inventor
Liat Dassa
Oren Bogin
Original Assignee
Immunorizon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunorizon Ltd filed Critical Immunorizon Ltd
Publication of MX2023013017A publication Critical patent/MX2023013017A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2023013017A 2021-05-04 2022-05-02 Anticuerpos anti citolítico natural grupo 2, miembro d (nkg2d) y usos de estos. MX2023013017A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163183635P 2021-05-04 2021-05-04
PCT/IL2022/050453 WO2022234571A2 (en) 2021-05-04 2022-05-02 Anti-nkg2d antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2023013017A true MX2023013017A (es) 2024-01-18

Family

ID=83932629

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013017A MX2023013017A (es) 2021-05-04 2022-05-02 Anticuerpos anti citolítico natural grupo 2, miembro d (nkg2d) y usos de estos.

Country Status (11)

Country Link
US (1) US20240228626A1 (https=)
EP (1) EP4333889A4 (https=)
JP (1) JP2024517741A (https=)
KR (1) KR20240004838A (https=)
CN (1) CN117396220A (https=)
AU (1) AU2022269411A1 (https=)
BR (1) BR112023023090A2 (https=)
CA (1) CA3217726A1 (https=)
IL (1) IL308204A (https=)
MX (1) MX2023013017A (https=)
WO (1) WO2022234571A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116199777B (zh) * 2021-12-01 2025-01-28 北京免疫方舟医药科技有限公司 抗hNKG2D抗体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008337517B2 (en) * 2007-12-14 2014-06-26 Novo Nordisk A/S Antibodies against human NKG2D and uses thereof
WO2010017103A2 (en) * 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
TWI622402B (zh) * 2010-02-24 2018-05-01 免疫遺傳股份有限公司 葉酸受體１抗體類和免疫共軛物類及彼等之用途
US9765151B2 (en) * 2013-03-11 2017-09-19 Cured Inc. Method for producing monoclonal IgA antibody
FI3380522T3 (fi) * 2015-11-25 2024-01-16 Visterra Inc Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä
WO2018030405A1 (ja) * 2016-08-09 2018-02-15 国立大学法人東京医科歯科大学 Ｈｍｇｂ１に対する抗体、及びそれを含有するアルツハイマー病を治療又は予防するための組成物
EP3927728A2 (en) * 2019-02-21 2021-12-29 Xencor, Inc. Untargeted and targeted il-10 fc-fusion proteins
CN113811546B (zh) * 2019-05-07 2025-03-11 免疫里森公司 前体三特异性抗体构建体及其使用方法
AR119393A1 (es) * 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
US20210024644A1 (en) * 2019-07-25 2021-01-28 Zomedica Pharmaceuticals Corp. N-cadherin binding molecules and uses thereof
CN116096754A (zh) * 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法

Also Published As

Publication number Publication date
US20240228626A1 (en) 2024-07-11
IL308204A (en) 2024-01-01
BR112023023090A2 (pt) 2024-01-30
EP4333889A2 (en) 2024-03-13
JP2024517741A (ja) 2024-04-23
EP4333889A4 (en) 2025-11-12
WO2022234571A3 (en) 2022-12-29
AU2022269411A1 (en) 2023-12-21
CN117396220A (zh) 2024-01-12
KR20240004838A (ko) 2024-01-11
WO2022234571A2 (en) 2022-11-10
CA3217726A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
Koneczny Update on IgG4-mediated autoimmune diseases: new insights and new family members
AU2019218516A1 (en) Antibodies to T cell immunoreceptor with ig and itim domains (TIGIT) and uses thereof
WO2019226514A3 (en) Molecular gene signatures and methods of using same
GEAP202416053A (en) Modified short interfering nucleic acid (sina) molecules and uses thereof
MX2022003930A (es) Conjugados de péptido de camptotecina.
MX2020010458A (es) Conjugados de camptotecina-peptido.
IL273841B1 (en) Antibodies targeting cd137 and methods of use thereof
WO2009055005A3 (en) Competitive inhibitors of invariant chain expression and/or ectopic clip binding
PH12022550211A1 (en) Anti-pd-1 antibody and medical use thereof
NZ607996A (en) Substituted nucleotide analogs
WO2008094510A3 (en) Methods of modulating immune function
RU2009138922A (ru) Новые анти-r7v-антитела и их применения
WO2020104649A3 (en) Novel rna compositions and methods for inhibiting angptl8
WO2022155541A8 (en) Interferon prodrugs and methods of making and using the same
MX2021006398A (es) Expansión de células asesinas naturales y células ilc3 con compuestos aromáticos novedosos.
JP2019524730A5 (https=)
WO2019117660A3 (ko) Crispr 시스템 기능 향상 방법 및 그의 이용
MX2023001287A (es) Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos.
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
WO2020252441A3 (en) Activated lymphocytic cells and methods of using the same to treat cancer and infectious conditions
MX2023013017A (es) Anticuerpos anti citolítico natural grupo 2, miembro d (nkg2d) y usos de estos.
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
WO2024083925A3 (en) Novel anti-napi2b antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
WO2022150654A3 (en) Antigen-binding polypeptides specific for coronaviruses and uses thereof
IL274363B2 (en) Use of specific sirna against protein s for the treatment of hemophilia